Laden...
| This week's FierceBiotech is brought to you by Hanson Wade. |
| As new technologies analyze more variables than ever before, binary biomarkers like PD-L1 expression are no longer sufficient to select patients for IO trials effectively. This was a key sentiment expressed by the industry leaders we have worked with to produce the 4th Annual ICI Boston Summit, taking place from March 19-21, 2018. The resulting agenda includes in-depth insights into the role of factors like mutational load, neoantigen expression and microsatellite instability. Join us for a comprehensive view of the latest immuno-oncology biomarker approaches. You can access the full brochure here. |
| What can you look forward to? Novartis will share how biomarker data from combination studies can be used to select patients for novel combo trials more effectively Jounce will present how they have linked preclinical biomarkers to patient enrichment strategies early on in clinical development to implement biomarker strategies with a solid biological understanding and grounding in data Dana-Farber will discuss the role the environment and human microbiome play in immune responses, enabling you to personalize your IO patient recruitment like never before |
| In addition, learn from the following IO pioneers: EMD Serono - Merck - Bristol-Myers Squibb - Genentech - MedImmune - Tesaro Seres Therapeutics - Regeneron Novartis - Providence Cancer Center - BeiGene Dana-Farber - Mitra Biotech - AstraZeneca - Bayer - University of Chicago Arcus Biosciences - Nodus Therapeutics - Jounce - Celldex - Trillium |
| Next steps? Download the latest agenda to see what our 30+ speakers will discuss. The early booking rate closes on Monday, January 15th. Save on your registration and book now. Make the most of the networking time and bring your team. Enquire about group discounts. |
| Q: Contact: David Snowdon Program Director Hanson Wade |
View our full Privacy Policy. © 2017 Hanson Wade Ltd, 52 Grosvenor Gardens, London, SW1W 0AU, United Kingdom. |
| Want to reach 150,000+ FierceBiotech subscribers with your own message?
FierceMarkets, a division of Questex, LLC |
Laden...
Laden...
© 2024
